Implementation and Evaluation of an Alternative Electronic Health Record Tool for Ordering Blood Products in Pediatric Oncology and Stem Cell Transplantation: Mixed Methods Analysis

Clinical Snapshot

Key Findings

• P Value: P<.001 for timing, guideline concordance, and irradiated product ordering

• Effect Size: Significant improvements in transfusion timing and safety metrics

• Primary Outcome: 59% of transfusions originated from therapy plans during post-implementation period, increasing to 71% in final month

• Nnt Or Sensitivity: Average avoidance of 4 overnight blood product entries per night

• Confidence Interval: Not reported for primary outcomes

Clinical Application

Requires compatible EHR system and institutional commitment to workflow redesign Relevant to Australian pediatric oncology centers using similar EHR systems; aligns with National Blood Authority patient blood management guidelines and TGA blood product safety requirements Pediatric oncology and stem cell transplant patients requiring frequent transfusions

Abstract

BACKGROUND: Repeated blood product ordering is associated with order entry errors and potential patient harm. Traditional electronic health record order sets require repeated re-entry for recurrent transfusions, creating inefficiencies and opportunities for error, and contributing to physician burnout. Historically, we have used order sets to order blood products, which must be re-entered each time a transfusion is needed. Reusable transfusion therapy plans may address these challenges by standardizing and streamlining transfusion workflows. We conducted a pre-post study at a single pediatric academic center, evaluating the implementation of reusable transfusion therapy plans for packed red blood cells and platelets in oncology patients and those undergoing hematopoietic stem cell transplantation. OBJECTIVE: The primary outcome was to evaluate the proportion of transfusions originating from the transfusion therapy plans during the postimplementation period. Secondary outcomes included evaluating (1) the proportion of eligible patients with applied transfusion therapy plans, (2) changes in transfusion efficiency (time from laboratory result to transfusion release and administration, premedication timing, and estimated overnight pages), and (3) the impact on safety (guideline-concordant dosing, irradiated product ordering, and transfusion thresholds). We also assessed health care practitioner experience using an adaptation of the technology acceptance model survey. METHODS: The prestudy period consisted of the 1-year preimplementation, and the postperiod consisted of the 1-year post implementation. We used our institution's enterprise data warehouse (SickKids Enterprise-Wide Data in Azure Repository) to obtain demographic and transfusion details for all eligible patients. The adapted technology acceptance model survey was administered to eligible oncology clinicians. RESULTS: The preimplementation cohort had 558 unique patients who received a total of 2678 transfusions. The postimplementation cohort had 521 unique patients who received 2777 transfusions. During the postimplementation period, 59% of transfusion orders originated from a therapy plan, increasing to 71% in the final month. Compared with order sets, therapy plan-derived transfusions were released and administered significantly faster following laboratory results (P<.001). Guideline-concordant transfusion volumes increased significantly postimplementation for both packed red blood cells and platelets (P<.001), as did the ordering of irradiated blood products (P<.001). No differences were observed in pretransfusion hemoglobin or platelet thresholds between study periods. Use of therapy plans was associated with an average avoidance of 4 overnight blood product entries per night. Survey responses from nurses and providers demonstrated high perceived usefulness and ease of use, with 95% endorsing continued use. CONCLUSIONS: Reusable transfusion therapy plans improved efficiency, standardized safe ordering practices, and were highly acceptable to clinicians. This longitudinal, noninterruptive electronic health record intervention represents a scalable approach to supporting high-risk transfusion workflows in pediatric oncology.

References

1. 1.Sarna, A., Finkelstein, A., Malcolmson, C., Potashner, R., Pitch, N., Forestieri, A., Cooper, M., Feng, Y., Patel, A., Schechter, T., Jessa, K., Sung, L., & Yan, A. P. (2026). Implementation and Evaluation of an Alternative Electronic Health Record Tool for Ordering Blood Products in Pediatric Oncology and Stem Cell Transplantation: Mixed Methods Analysis. JMIR Medical Informatics. https://doi.org/10.2196/93346